Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Capital Expenditures (2019 - 2025)

SRx Health Solutions (SRXH) has disclosed Capital Expenditures for 7 consecutive years, with $7000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Capital Expenditures rose 133.33% year-over-year to $7000.0, compared with a TTM value of $1.0 million through Mar 2025, up 9145.45%, and an annual FY2023 reading of $18000.0, down 90.91% over the prior year.
  • Capital Expenditures was $7000.0 for Q1 2025 at SRx Health Solutions, down from $11000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $996000.0 in Q2 2024 and bottomed at $3000.0 in Q1 2024.
  • Average Capital Expenditures over 5 years is $132166.7, with a median of $25000.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures surged 2800.0% in 2021, then tumbled 93.33% in 2023.
  • Year by year, Capital Expenditures stood at $229000.0 in 2021, then plummeted by 96.07% to $9000.0 in 2022, then fell by 11.11% to $8000.0 in 2023, then soared by 37.5% to $11000.0 in 2024, then tumbled by 36.36% to $7000.0 in 2025.
  • Business Quant data shows Capital Expenditures for SRXH at $7000.0 in Q1 2025, $11000.0 in Q3 2024, and $996000.0 in Q2 2024.